Cryptotanshinone (CPT) has shown anti-inflammatory and neuroprotective effects in mouse models of Alzheimer's disease (AD) by significantly reducing the expression of S100β, GFAP, COX-2, iNOS, and NFkBp6530. Here, PTGS2 is linked to early-onset autosomal dominant Alzheimer disease.